Decipher Labs Ltd Stock Price Today (NSE: DECIPHER)
Fundamental Score
Decipher Labs Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Decipher Labs Ltd share price today is ₹5.00, down 11.61% on NSE/BSE as of 30 March 2026. Decipher Labs Ltd (DECIPHER) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹10.41 (Cr). The 52-week high for DECIPHER share price is ₹12.50 and the 52-week low is ₹5.30. The company has a Return on Equity (ROE) of 1.16% and a debt-to-equity ratio of 0.02.
Decipher Labs Ltd Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Decipher Labs Ltd Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Decipher Labs Share Price: ROCE Efficiency Under Scrutiny
The pharmaceutical industry is currently navigating a landscape of heightened regulatory scrutiny and increasing R&D costs, making efficient capital allocation crucial for success. Our analysis focuses on Decipher Labs share price, currently trading at ₹7.75. A preliminary glance reveals the company operates without a positive Price-to-Earnings (PE) ratio and a Return on Capital Employed (ROCE) of -4.67%. This analysis forms part of a comprehensive 80-parameter fundamental audit, verified by Sweta Mishra.
The negative ROCE figure presents a significant area of concern. ROCE, a critical metric for evaluating profitability relative to capital employed, indicates that Decipher Labs is currently generating negative returns on its investments. This directly impacts the company's ability to build a sustainable economic moat. A robust moat, often built through innovation and cost efficiency, is difficult to establish when capital is not being deployed effectively. A negative ROCE suggests potential inefficiencies in operational processes, product development, or market penetration strategies.
When assessing companies within the pharmaceutical sector, it's vital to compare their performance against established players. For example,
Mankind Pharma Ltd is known to deliver positive returns. This is often attributed to strong execution, efficient supply chain management, and perhaps a more effective resource allocation strategy driven by experienced management. The contrast with Decipher Labs Ltd highlights the importance of management quality and its impact on financial performance.Ultimately, a negative ROCE can erode investor confidence and limit the company's access to capital. While the low share price might present an apparent opportunity, a deeper investigation into the underlying causes of the negative ROCE is warranted. A turnaround strategy focused on improving capital efficiency, optimizing operational costs, and enhancing product offerings could potentially improve future performance. However, observable financial indicators suggest the current situation demands caution.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Decipher Labs Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of DECIPHER across key market metrics for learning purposes.
Positive Indicators
3 factors identified
Robust Profit Growth (101.50%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Conservative Debt Levels (D/E: 0.02)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
9 factors identified
Below-Average Return on Equity (1.16%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (-4.67%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Margin Pressure Concerns (1.23%)
Observation: Operating margins are below industry standards.
Analysis: OPM <5% may indicate pricing pressures or cost management challenges.
Revenue Contraction (-26.58%)
Observation: Sales decline may indicate market challenges or competitive pressures.
Analysis: Negative revenue growth requires analysis of market conditions.
Limited Growth History (-1.18% CAGR)
Observation: Below-average 5-year sales growth trajectory.
Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities.
Weak Earnings Growth (-25.06% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Stagnant Profit Growth (-25.06% CAGR)
Observation: Limited 5-year profit growth trajectory.
Analysis: Low profit growth may indicate scalability challenges or market maturity.
Low Promoter Commitment (16.43%)
Observation: Reduced promoter stake may indicate limited confidence.
Analysis: Low promoter holding may raise questions about management commitment.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Decipher Labs Ltd Financial Statements
Comprehensive financial data for Decipher Labs Ltd including income statement, balance sheet and cash flow
About DECIPHER (Decipher Labs Ltd)
Decipher Labs Ltd is a dynamic pharmaceutical company dedicated to unraveling complex health challenges through innovative drug development and strategic partnerships. With a focus... on both domestic and international markets, DECIPHER strives to deliver high-quality pharmaceutical solutions that improve patient outcomes. The company's research and development efforts are geared towards identifying novel therapeutic targets and formulating effective treatments for a wide range of diseases. DECIPHER is committed to maintaining the highest standards of quality and regulatory compliance across all its operations, from drug discovery to manufacturing and distribution. Beyond pharmaceuticals, DECIPHER also leverages its expertise in technology to offer specialized IT solutions, fostering synergy between healthcare and technological advancements. At the core of DECIPHER's operations are two key divisions: Pharmaceutical and Consultancy. The Pharmaceutical division is responsible for the development, manufacturing, and commercialization of a diverse portfolio of pharmaceutical products, including branded formulations, finished drugs, and essential chemical compounds. The Consultancy division provides comprehensive IT services tailored to the needs of the healthcare industry, offering technology integration, systems consulting, and software development expertise. By combining its pharmaceutical capabilities with its technological prowess, DECIPHER aims to revolutionize healthcare delivery and improve access to innovative treatments for patients worldwide. Decipher Labs Ltd is driven by a team of experienced scientists, healthcare professionals, and technology experts who are passionate about making a positive impact on global health. The company's commitment to research and development, coupled with its dedication to ethical business practices, positions it as a trusted partner in the pharmaceutical industry. DECIPHER's unwavering focus on innovation, quality, and customer satisfaction ensures that it remains at the forefront of pharmaceutical advancements, while its commitment to corporate social responsibility drives it to contribute to the well-being of communities around the world.
Company Details
Key Leadership
Latest News
DECIPHER Share Price: Frequently Asked Questions
What is the current share price of Decipher Labs Ltd (DECIPHER)?
As of 30 Mar 2026, 12:02 pm IST, Decipher Labs Ltd share price is ₹5.00. The DECIPHER stock has a market capitalisation of ₹10.41 (Cr) on NSE/BSE.
Is DECIPHER share price Overvalued or Undervalued?
DECIPHER share price is currently trading at a P/E ratio of 0.00x, compared to the industry average of 31.77x. Based on this relative valuation, the Decipher Labs Ltd stock appears to be Fairly Valued against its sector peers.
What is the 52-week high and low of DECIPHER share price?
The 52-week high of DECIPHER share price is ₹12.50 and the 52-week low is ₹5.30. These values are updated daily from NSE/BSE price data.
What factors affect the Decipher Labs Ltd share price?
Key factors influencing DECIPHER share price include quarterly earnings growth (Sales Growth: -26.58%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Decipher Labs Ltd a good stock for long-term investment?
Decipher Labs Ltd shows a 5-year Profit Growth of -25.06% and an ROE of 1.16%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.02 before investing in DECIPHER shares.
How does Decipher Labs Ltd compare with its industry peers?
Decipher Labs Ltd competes with major peers in the Pharmaceuticals. Investors should compare DECIPHER share price P/E of 0.00x and ROE of 1.16% against the industry averages to determine competitive standing.
What is the P/E ratio of DECIPHER and what does it mean?
DECIPHER share price has a P/E ratio of N/Ax compared to the industry average of 31.77x. Investors pay ₹N/A for every ₹1 of annual earnings.
How is DECIPHER performing according to Bull Run's analysis?
DECIPHER has a Bull Run fundamental score of 9/100, indicating concerns requiring careful analysis. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does DECIPHER belong to?
DECIPHER operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Decipher Labs Ltd share price.
What is Return on Equity (ROE) and why is it important for DECIPHER?
DECIPHER has an ROE of 1.16%, which suggests challenges in generating returns from shareholders equity. ROE measures how efficiently Decipher Labs Ltd generates profits from shareholders capital.
How is DECIPHER debt-to-equity ratio and what does it indicate?
DECIPHER has a debt-to-equity ratio of 0.02, which indicates conservative financing with low financial risk.
What is DECIPHER dividend yield and is it a good dividend stock?
DECIPHER offers a dividend yield of 0.00%, meaning you receive ₹0.00 annual dividend for every ₹100 invested in Decipher Labs Ltd shares.
How has DECIPHER share price grown over the past 5 years?
DECIPHER has achieved 5-year growth rates of: Sales Growth -1.18%, Profit Growth -25.06%, and EPS Growth -25.06%.
What is the promoter holding in DECIPHER and why does it matter?
Promoters hold 16.43% of DECIPHER shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in Decipher Labs Ltd.
What is DECIPHER market capitalisation category?
DECIPHER has a market capitalisation of ₹10 crores, placing it in the Small-cap category.
How volatile is DECIPHER stock?
DECIPHER has a beta of N/A. A beta > 1 suggests the Decipher Labs Ltd stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is DECIPHER operating profit margin trend?
DECIPHER has a 5-year average Operating Profit Margin (OPM) of 1.23%, indicating the company's operational efficiency.
How is DECIPHER quarterly performance?
Recent quarterly performance shows Decipher Labs Ltd YoY Sales Growth of -26.58% and YoY Profit Growth of 101.50%.
What is the institutional holding pattern in DECIPHER?
DECIPHER has FII holding of 0.00% and DII holding of 0.00%. Significant institutional holding often suggests professional confidence in the Decipher Labs Ltd stock.